We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > AVB-500

News List

Aravive Announces Dose Escalation of AVB-500 in Ovarian Cancer Treatment Trial americanpharmaceuticalreview
March 10, 2020
Aravive announced the independent Data Monitoring Committee (DMC) has reviewed the open-label data following the first 28-day treatment cycle for the three patients in each of the two 15 mg/kg dosing cohorts of the Phase 1b portion of ...
Aravive Receives IND Clearance for AVB-500 Trial for Clear Cell Renal Cell Carcinoma americanpharmaceuticalreview
January 17, 2020
Aravive announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for investigation of the company’s lead candidate, AVB-500, for the treatment of clear cell renal cell carcinoma (ccRCC
Aravive Initiates Trial of AVB-500 in Patients with Kidney Fibrosis americanpharmaceuticalreview
December 23, 2019
Aravive announced the company has begun enrolling patients in the Phase 2a clinical trial of AVB-500 in patients with kidney fibrosis, specifically IgA Nephropathy (IgAN).